Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
22
GTBP Quote, Financials, Valuation and Earnings
Last price:
$0.82
Seasonality move
:
-3.8%
Day range:
$0.75 - $0.84
52-week range:
$0.54 - $3.85
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
59.35x
P/B ratio:
2.78x
Volume:
1.7M
Avg. volume:
1.6M
1-year change:
-74.26%
Market cap:
$8.4M
Revenue:
--
EPS (TTM):
-$3.40
Analysts' Opinion
-
Consensus RatingGT Biopharma, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $8.00, GT Biopharma, Inc. has an estimated upside of 918.85% from its current price of $0.79.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $8.00 representing 100% downside risk from its current price of $0.79.
Fair Value
-
According to the consensus of 1 analyst, GT Biopharma, Inc. has 918.85% upside to fair value with a price target of $8.00 per share.
GTBP vs. S&P 500
-
Over the past 5 trading days, GT Biopharma, Inc. has underperformed the S&P 500 by -1.26% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
GT Biopharma, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
GT Biopharma, Inc. revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter GT Biopharma, Inc. reported revenues of --.
Earnings Growth
-
GT Biopharma, Inc. has grown year-over-year earnings for 5 quarters straight. In the most recent quarter GT Biopharma, Inc. reported earnings per share of -$0.83.
Enterprise value:
5.7M
EV / Invested capital:
--
Price / LTM sales:
59.35x
EV / EBIT:
--
EV / Revenue:
34.30x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-0.50x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-181.28%
Net Income Margin (TTM):
--
Return On Equity:
-626.24%
Return On Invested Capital:
-626.24%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$16.2M | -$13.8M | -$10.6M | -$3.6M | -$3.4M | |
| EBITDA | -$16.2M | -$13.8M | -$10.6M | -$3.6M | -$3.4M | |
| Diluted EPS | -$8.55 | -$7.48 | -$3.40 | -$1.53 | -$0.83 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $35.8M | $20.9M | $16.1M | $6.8M | $3.6M | |
| Total Assets | $35.8M | $21.1M | $16.1M | $6.8M | $4.3M | |
| Current Liabilities | $3.9M | $5M | $5.1M | $4.7M | $1.3M | |
| Total Liabilities | $3.9M | $5.1M | $6.1M | $4.7M | $1.3M | |
| Total Equity | $31.9M | $16M | $10M | $2.1M | $3M | |
| Total Debt | -- | $92K | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$11.1M | -$12.5M | -$11.4M | -$2.7M | -$3.7M | |
| Cash From Investing | $5M | $13.4M | $1K | -$1K | -- | |
| Cash From Financing | $6.3M | $3M | $7.5M | -- | $977K | |
| Free Cash Flow | -$11.1M | -$12.5M | -$11.4M | -$2.7M | -$3.7M | |
GTBP
Sector
Market Cap
$8.4M
$28.1M
Price % of 52-Week High
20.4%
50%
Dividend Yield
0%
0%
Shareholder Yield
-212.85%
-1.54%
1-Year Price Total Return
-74.26%
-17.67%
Beta (5-Year)
1.172
0.503
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.81
200-day SMA
Sell
Level
$1.63
Bollinger Bands (100)
Sell
Level
0.57 - 1.09
Chaikin Money Flow
Sell
Level
-48.9M
20-day SMA
Buy
Level
$0.72
Relative Strength Index (RSI14)
Buy
Level
53.21
ADX Line
Buy
Level
37.33
Williams %R
Neutral
Level
-50.1104
50-day SMA
Buy
Level
$0.70
MACD (12, 26)
Buy
Level
0.03
25-day Aroon Oscillator
Buy
Level
72
On Balance Volume
Neutral
Level
176.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-240.9713)
Sell
CA Score
(Annual)
Level (-8.3692)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (16.2136)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in San Francisco, CA.
Stock Forecast FAQ
In the current month, GTBP has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The GTBP average analyst price target in the past 3 months is $8.00.
-
Where Will GT Biopharma, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that GT Biopharma, Inc. share price will rise to $8.00 per share over the next 12 months.
-
What Do Analysts Say About GT Biopharma, Inc.?
Analysts are divided on their view about GT Biopharma, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that GT Biopharma, Inc. is a Sell and believe this share price will drop from its current level to $8.00.
-
What Is GT Biopharma, Inc.'s Price Target?
The price target for GT Biopharma, Inc. over the next 1-year time period is forecast to be $8.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is GTBP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for GT Biopharma, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of GTBP?
You can purchase shares of GT Biopharma, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase GT Biopharma, Inc. shares.
-
What Is The GT Biopharma, Inc. Share Price Today?
GT Biopharma, Inc. was last trading at $0.82 per share. This represents the most recent stock quote for GT Biopharma, Inc.. Yesterday, GT Biopharma, Inc. closed at $0.79 per share.
-
How To Buy GT Biopharma, Inc. Stock Online?
In order to purchase GT Biopharma, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get GTBP Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
GTBP
Sector
P/E ratio
--
23.88x
PEG ratio
0.00x
-0.01x
P/B ratio
2.78x
1.82x
Price / LTM sales
59.35x
1.59x
Growth Metrics
GTBP
Sector
Revenue growth
--
4.73%
Earnings growth
45.84%
11.11%
Revenue (5-year growth)
--
6.46%
Earnings forecast
--
-$0.18
Profitability
GTBP
Sector
Profitability FY 2024
--
$3.6M
Return on invested capital
-626.24%
-31.77%
Return on assets
-181.28%
-28.18%
Return on equity
-626.24%
-37.47%
Earnings Date
Last Earnings Date
May
13
Next Earnings Date
Jan
2
Estimated Next Earnings Date
Apr
3
Balance Sheet
GTBP
Sector
Total cash
$2.6M
$26.3M
Short term investments
--
$26M
Total assets
$4.2M
$76.9M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 2
Corcept Therapeutics, Inc. [CORT] is up 6.12% over the past day.
Buy
75
AXSM alert for Jan 2
Axsome Therapeutics, Inc. [AXSM] is down 3.13% over the past day.
Sell
50
NUTX alert for Jan 2
Nutex Health, Inc. [NUTX] is down 7.67% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
